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Glucose clamp studies form an integral part of the early development of insulin therapies. Data generated in these studies 
are used to establish pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the agents, but methodological differences 
confound comparison of results from different glucose clamp studies. The first part of this series on glucose clamp studies 
discussed practical tips for the interpretation of glucose clamp studies. The second part of the series compares the PK/PD profiles 
of longer-acting basal analogue insulins, insulin degludec (IDeg) and insulin glargine U300 (Gla-300). The patient populations 
for glucose clamp studies with these analogue insulins differ, and therefore direct comparison of the data is not always possible. 
The maximum duration of action of IDeg is reported as 42 h and that of Gla-300 as 36 h, translating to 24 h coverage. The plasma 
insulin concentration of IDeg is 56 times that of Gla-300. Results from phase III clinical trials for these analogue insulins confirm 
the predictability and low within-subject variability observed in glucose clamp studies. Insight into the PK/PD profiles of longer-
acting basal analogue insulins allows the treating physician to utilise these characteristics to optimise the treatment of their 
patients with diabetes.
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Introduction
Exogenous insulin is used to treat hyperglycaemia in selected 
patients diagnosed with diabetes mellitus (DM). In order to 
mimic physiological insulin secretion, treatment with long-
acting basal insulins, as well as rapid-acting insulins, may be 
required.1
The ideal longer-acting analogue insulin will display flat, peakless 
pharmacokinetic (PK) and pharmacodynamic (PD) profiles with 
limited inter- and intra-individual variability. The time–activity 
profile of an analogue insulin is determined with a glucose clamp 
study. A glucose clamp study measures the amount of glucose 
required to maintain the plasma glucose concentration at a 
predetermined level referred to as the clamp target, in terms of 
the glucose infusion rate (GIR), which provides a way to describe 
the PD profile of the study insulin. The pharmacokinetic profile of 
the study insulin is determined by the plasma insulin 
concentration over time, as observed during the glucose clamp 
study.
A major concern with the use of exogenous insulin is the 
potential for causing hypoglycaemia. The PK/PD properties of an 
analogue insulin, as determined during early clinical 
development, can be used to predict the potential, be it high or 
low, of the insulin to induce hypoglycaemia. These results are 
later confirmed in pivotal clinical trials. Ideally, an analogue 
insulin should present with a peakless PK profile, which translates 
into constant and predictable plasma insulin concentration and 
reduced risk for hypoglycaemia.2 In contrast, high variability in 
the PK profile indicates a higher probability of hypoglycaemia 
episodes and difficulty in titrating a patient’s exogenous insulin 
treatment to a required glucose target.
Since insulin production became possible, numerous insulin 
preparations have been developed that necessitated multiple 
daily administrations due to insufficient duration of action to 
provide basal insulin coverage for 24  h.3 The first long-acting 
basal analogue insulin produced was insulin glargine, referred to 
as Gla-100. During the development of Gla-100 an amino acid 
substitution was made at position A21, glycine for asparagine.4 
This amino acid substitution improved the stability of the 
molecule and extended its duration of action. The duration of 
action of Gla-100 is reported to be 24 h3, translating into once-
daily administration. Gla-100 also shows a smaller gradient in its 
PK profile than NPH or regular human insulin, as well as reduced 
variability.
However, to accurately replicate physiological basal insulin 
coverage, duration of action exceeding 24 h is required with a 
peakless PD (time–activity) profile to further minimise the risk of 
hypoglycaemia.5 To address the current unmet need in basal 
analogue insulins, two longer-acting insulin analogues have 
been developed: insulin degludec (IDeg) and insulin glargine 
U300 (Gla-300). As part of the clinical development plan of these 
analogue insulins, glucose clamp studies were performed to 
determine their PK and PD profiles. While no head-to-head 
glucose clamp data are currently available comparing the PK/PD 
profiles of IDeg and Gla-300, the results of numerous glucose 
clamp studies have been published for these two molecules 
separately.
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Introduction
Exogenous insulin is used to treat hyperglycaemia in selected 
patients diagnosed with diabetes mellitus (DM). In order to 
mimic physiological insulin secretion, treatment with long-
acting basal insulins, as well as rapid-acting insulins, may be 
required.1
The ideal longer-acting analogue insulin will display flat, peakless 
pharmacokinetic (PK) and pharmacodynamic (PD) profiles with 
limited inter- and intra-individual variability. The time–activity 
profile of an analogue insulin is determined with a glucose clamp 
study. A glucose clamp study measures the amount of glucose 
required to maintain the plasma glucose concentration at a 
predetermined level referred to as the clamp target, in terms of 
the glucose infusion rate (GIR), which provides a way to describe 
the PD profile of the study insulin. The pharmacokinetic profile of 
the study insulin is determined by the plasma insulin 
concentration over time, as observed during the glucose clamp 
study.
A major concern with the use of exogenous insulin is the 
potential for causing hypoglycaemia. The PK/PD properties of an 
analogue insulin, as determined during early clinical 
development, can be used to predict the potential, be it high or 
low, of the insulin to induce hypoglycaemia. These results are 
later confirmed in pivotal clinical trials. Ideally, an analogue 
insulin should present with a peakless PK profile, which translates 
into constant and predictable plasma insulin concentration and 
reduced risk for hypoglycaemia.2 In contrast, high variability in 
the PK profile indicates a higher probability of hypoglycaemia 
episodes and difficulty in titrating a patient’s exogenous insulin 
treatment to a required glucose target.
Since insulin production became possible, numerous insulin 
preparations have been developed that necessitated multiple 
daily administrations due to insufficient duration of action to 
provide basal insulin coverage for 24  h.3 The first long-acting 
basal analogue insulin produced was insulin glargine, referred to 
as Gla-100. During the development of Gla-100 an amino acid 
substitution was made at position A21, glycine for asparagine.4 
This amino acid substitution improved the stability of the 
molecule and extended its duration of action. The duration of 
action of Gla-100 is reported to be 24 h3, translating into once-
daily administration. Gla-100 also shows a smaller gradient in its 
PK profile than NPH or regular human insulin, as well as reduced 
variability.
However, to accurately replicate physiological basal insulin 
coverage, duration of action exceeding 24 h is required with a 
peakless PD (time–activity) profile to further minimise the risk of 
hypoglycaemia.5 To address the current unmet need in basal 
analogue insulins, two longer-acting insulin analogues have 
been developed: insulin degludec (IDeg) and insulin glargine 
U300 (Gla-300). As part of the clinical development plan of these 
analogue insulins, glucose clamp studies were performed to 
determine their PK and PD profiles. While no head-to-head 
glucose clamp data are currently available comparing the PK/PD 
profiles of IDeg and Gla-300, the results of numerous glucose 
clamp studies have been published for these two molecules 
separately.
Following on from the practical tips for interpreting the results of 
glucose clamp studies in part one of this series, the PK/PD profiles 
of IDeg and Gla-300 will now be discussed.
Published glucose clamp data on IDeg and Gla-
300
In the previous part of this series on the interpretation of glucose 
clamp studies, six main aspects of glucose clamp studies to 
consider when interpreting results were suggested: (1) clamp 
methodology, (2) duration of glucose clamp study, (3) study 
population, (4) dose of study insulin, (5) glucose infusion rate 
and (6) plasma insulin concentration. Following is a practical 
application of these points to compare results published from 
glucose clamp studies of IDeg and Gla-300.
Clamp methodology
Glucose clamp studies can be performed manually, where plasma 
glucose levels are measured in intervals of several minutes and 
the glucose infusion rate is manually adjusted to maintain clamp 
target, or with the use of a Biostator MTB (Medizintechnik, 
Amstetten, Germany), allowing for determination of glucose 
levels every minute and automated adjustment of the glucose 
infusion rate. The use of the Biostator in glucose clamp studies 
eliminates potential biased adjustment of the glucose infusion 
rate and allows for standardisation of study conditions.6 Published 
glucose clamp studies of IDeg7–9 and Gla-3005,10–12 made use of a 
Biostator. As is standard practice in glucose clamp studies using 
Biostators, study participants in all glucose clamp studies with 
IDeg and Gla-300 were connected to the Biostator several hours 
prior to initiation of the clamp procedure as part of a stabilisation 
period.
Duration of glucose clamp study
The clinically appropriate end of the glucose clamp study is 
defined as the point in time when clamp target glucose level is 
maintained at GIR = 0 mg/kg/min.13 Therefore, the action of the 
study insulin has diminished to such an extent that blood 
glucose levels remain at clamp target without infusion of 
glucose. However, the duration of action of the study insulin may 
exceed the duration of the glucose clamp study. The duration of 
glucose clamp studies for longer-acting basal analogue insulins 
often exceeds 24  h. Indeed, the duration of glucose clamp 
studies performed for IDeg ranged from 24 h7,8 to 42 h9 and that 
of Gla-300 from 24 h12 to 36 h.5,10,11
Based on the results of the glucose clamp study with the longest 
duration, the half-life of IDeg has been reported as exceeding 
24 h and its duration of action as more than 42 h.9 The GIR had 
not reached 0  mg/kg/min at the 42  h mark and thus it was 
concluded that the duration of action of IDeg exceeded the 
duration of the clamp study.9 During this study, the mean half-
life of the three concentrations of IDeg used was calculated as 
25.4 h.9
The duration of glucose clamp studies for Gla-300 has not 
extended beyond 36 h. Of the three studies with a duration of 
36  h, only one conclusively showed GIR  =  0  mg/kg/min at the 
36 h mark.10 It can be argued that as GIR = 0 mg/kg/min had not 
been reached in the other glucose clamp studies with 36  h 
duration11,12, the duration of action of Gla-300 may exceed the 
duration of the clamp studies.
The longer-acting basal analogue insulins, IDeg and Gla-300, will 
provide basal insulin coverage exceeding 24  h. The extended 
duration of action may translate into greater flexibility in dosing 
than was possible with previous basal analogue insulins. 
However, as the true duration of action of these insulins cannot 
be accurately determined, it is not possible to estimate the total 
plasma insulin concentration from these results.
Study population
The patient population for glucose clamp studies can be selected 
to limit the effect of endogenous insulin secretion on PK/PD 
parameter estimations. Glucose clamp studies performed in a 
Type 1 DM patient population is considered to be ideal as the 
effect of endogenous insulin secretion is eliminated. However, as 
the real-world patient population mainly consists of patients 
diagnosed with Type 2 DM, it is valuable to obtain PK/PD data in 
a Type 2 DM patient population as well.13,14 In fact, true PK/PD 
estimates for the larger patient population can therefore only be 
determined from studies based on a truly representative study 
population.
In order to confirm low residual endogenous insulin secretion in 
the glucose clamp population of patients diagnosed with Type 1 
DM, the fasting serum C-peptide concentration is often 
determined. C-peptide is released upon the conversion of pre-
insulin to insulin and therefore provides an accurate measure of 
endogenous insulin secretion.15 The fasting serum C-peptide 
concentration for participants in IDeg glucose clamp studies was 
below 0.3 nmol/l.8,9 Similarly, glucose clamp studies for patients 
diagnosed with Type 1 DM for Gla-300 required a fasting serum 
C-peptide concentration below 0.3  nmol/l.5,10–12 Therefore, the 
potential for endogenous insulin to interfere in these glucose 
clamp studies was negligible.
In order to control for the effect of endogenous insulin in patients 
diagnosed with Type 2 DM, low fasting C-peptide levels are often 
required for inclusion of patients diagnosed with Type 2 diabetes 
in glucose clamp studies.16 As such, inclusion criteria for patients 
diagnosed with Type 2 DM for IDeg included a fasting serum 
C-peptide concentration below 1.0  nmol/l.7 Glucose clamp 
studies for Gla-300 have not been conducted in patients 
diagnosed with Type 2 DM. These levels of fasting serum C-peptide 
would eliminate the inclusion of patients with endogenous 
insulin secretion, which may confound results obtained.
One way to address the issue of inter-individual variability in trials 
is to use a crossover study design. This design is commonly used 
whereby a single patient population is used to investigate the PK/
PD parameters of the study and comparator insulin. This design 
reduces the number of volunteers required and yields more 
comparable results between the study and comparator insulin as 
the degree of insulin resistance, rate of insulin metabolism and 
other patient-specific factors remain constant between study 
groups. This type of design provides less confounded estimates 
of PK/PD parameters, which is why it was used in all of the glucose 
clamp studies discussed here, except one.8
Dose of study insulin
The dosages of study insulin and conditions for investigating the 
time–action profile of longer-acting basal analogue insulins 
should reflect those of the general treatment population. 
Therefore, the use of reasonable insulin doses at steady-state 
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conditions are regarded as the most appropriate for use in 
glucose clamp studies.13
Multiple concentrations of study insulin are usually investigated 
during glucose clamp studies. PK/PD profiles of IDeg were 
determined at concentrations of 0.4, 0.6 and 0.8 IU/kg for patients 
diagnosed with Type 2 DM7 or Type 1 DM9 and 0.4  IU/kg for 
patients diagnosed with Type 1 DM.8 Gla-300 was used at 
concentrations of 0.4 and 0.6  IU/kg,10–12 with the European 
population in the Shiramoto study also receiving Gla-300 at 
0.9 IU/kg.11
It was recently reported that the average daily basal insulin dose 
of patients diagnosed with T2DM is 0.41 ± 0.43 IU/kg,17 suggesting 
that the doses of IDeg and Gla-300 used in glucose clamp studies 
were clinically relevant. However, it must be considered that in 
the general treatment population titration and adjustment of 
insulin doses occur frequently and therefore the fixed 
concentrations of study insulin selected for the glucose clamp 
study may not accurately reflect clinical practice.9
As the conditions of the study population in glucose clamp 
studies should reflect the conditions in the general treatment 
population, the use of steady-state conditions is recommended 
as this most accurately replicates the use of long-acting analogue 
insulins in the treatment population.13 Steady-state conditions 
were used for glucose clamp studies investigating the PK/PD 
profile of IDeg.7–9 However, glucose clamp studies for Gla-300 
were performed after a single subcutaneous dose11 and under 
steady-state conditions.5,10,12
Shiramoto et al. reported the results of glucose clamp studies 
performed after a single subcutaneous dose of Gla-300 in 
Japanese patients diagnosed with Type 1 DM.11 In this study a 
single subcutaneous dose of 0.4 or 0.6  IU/kg Gla-300 was 
administered after an overnight fast. A maximum insulin 
concentration (Cmax) of 10.9 μU/ml was recorded over the 36  h 
clamp period after a single administration of 0.4  IU/kg of Gla-
300.11 However, where glucose clamp studies were performed in 
patients diagnosed with Type 1 DM at steady-state conditions, 
i.e. after daily administration of 0.4 IU/kg Gla-300 for 8 days, Cmax 
was recorded as 18.1 μU/ml over the 36 h clamp period,10 almost 
double the concentration reported in the single-dose study. In 
the general treatment population it is more likely that patients 
will receive daily doses of insulin, and therefore PK/PD parameters 
reported at steady-state conditions are more clinically relevant.
Glucose infusion rate
The GIR is adjusted according to measured blood glucose values 
to maintain blood glucose levels at predetermined clamp 
targets. GIR is the main PD endpoint determined during glucose 
clamp studies. Fluctuation in the GIR observed during the clamp 
study is indicative of intra-individual variation in response and 
may translate into unpredictable intra-individual response. 
Fluctuation in GIR is often reported as the coefficient of variation 
(CV).16
From a clinical perspective, intra-individual variation may be the 
most relevant parameter. Intra-individual variation affects the 
predictability of an individual’s response to treatment. 
Unfortunately, not all studies report on these parameters.
Intra-individual variation of 20% in total GIR was reported for a 
clamp study performed with IDeg at a concentration of 0.4 IU/kg 
under steady-state conditions in a study population of 54 Type 1 
DM patients.8 After a 24 h euglycemic clamp study in 50 Type 1 
DM patients receiving 0.4  IU/kg of Gla-300, an intra-individual 
variation of 34.8% in total GIR was reported under steady-state 
conditions.12 Data thus indicate that a lower intra-individual 
variability, and therefore potentially a more reliable patient 
response, may be achieved with IDeg in a Type 1 DM treatment 
population. However, this still requires confirmation with results 
from pivotal clinical studies.
Inter-individual variability predicts the treatment population’s 
response to treatment. Unfortunately, the inter-individual 
variability was not reported in clamp studies of IDeg performed 
in patients diagnosed with Type 1 DM. Inter-individual variability 
in total GIR was reported as 43.2% under steady-state conditions 
in a study population of Type 1 DM patients treated with 0.4 IU/
kg of Gla-300.12
Inter-individual variability for IDeg is available for a Type 2 DM 
treatment population: the total GIR of glucose clamp studies 
performed with IDeg at a concentration of 0.4 IU/kg has reported 
an inter-individual variability of 67.9% under steady-state 
conditions in a study population of patients diagnosed with Type 
2 DM.7 However, data on the inter-individual variability in a Type 
2 DM treatment population for Gla-300 are not currently 
available. As the inter-individual variability reported was not 
obtained in the same treatment population, accurate comparison 
of the data is not possible. As these results are not available, 
there is no indication of the variation expected between patients 
being titrated in a similar manner and therefore the reliability of 
a physician achieving the correct dose for a specific patient if he/
she uses the same approach for all patients.
A caveat in the design of glucose clamp studies is the use of 
rapid-acting insulin when establishing clamp target. To establish 
the euglycemic clamp target, most patients require a glucose 
infusion. However, when plasma glucose concentrations become 
hyperglycaemic, rapid-acting insulin analogues or human insulin 
may be used to re-establish the euglycemic clamp levels. For 
IDeg clamp studies rapid-acting human regular insulin was used 
up to 10 min before dosing of the study insulin,7–9 while Gla-300 
studies made use of insulin glulisine. The duration of action of 
human regular insulin is estimated at seven hours18 and that of 
insulin glulisine at one to two and a half hours.3
As the infusion of rapid-acting human regular insulin and insulin 
glulisine were terminated shortly prior to initiation of the glucose 
clamp, these insulins may affect the glucose infusion rate 
required to maintain the clamp target. For studies using regular 
human insulin, this effect may influence the GIR for up to eight 
hours, while the GIR of studies using insulin glulisine may be 
affected for up to two and a half hours.
The total GIR over clamp period is often expressed as the GIR 
area under the curve (AUC) or GIR-AUC. Where the duration of 
the clamp is 24 h, the GIR of the study can be visualised at six-
hourly intervals, allowing for an overall view of the distribution of 
the study insulin effect over 24 h. The GIR-AUC of IDeg and Gla-
300 over six-hourly intervals as proportions of the total GIR-AUC 
is shown in Figure 1.
The PD profiles of both IDeg and Gla-300 demonstrate duration 
of action exceeding 24 h with minimal fluctuation in GIR between 
the different six-hourly intervals. A slight increase in GIR is 
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of the study insulin is measured during the glucose clamp study. 
The assays used to determine these concentrations are highly 
sensitive and specific to the study insulin, and therefore the 
concentration of residual endogenous insulin, in the case of a 
study population of patients diagnosed with Type 2 DM, or other 
insulins used to establish the clamp target should not interfere.
IDeg is highly plasma protein bound due to acylation of the B 
chain.20,21 Its high binding affinity for serum albumin translates 
into an extended duration of action,20 but may confound 
accurate quantification of plasma insulin concentrations. Using 
currently available immunoassays only the concentration of the 
free, unbound fraction of IDeg can be quantified.
The method used for the determination of serum IDeg 
concentrations was not discussed.8 In one glucose clamp study 
the serum IDeg concentration was quantified using a specific 
sandwich enzyme-linked immunosorbent assay (ELISA) using a 
mouse monoclonal antibody specific for human insulin.7,9 The 
study population of one of these studies consisted of patients 
diagnosed with Type 2 DM with confirmed fasting serum 
C-peptide concentrations below 1.0 nmol/l, effectively excluding 
participants with residual endogenous insulin secretion. It must 
be considered that this method is suited to quantify only the 
free, and pharmacologically active, IDeg, which may result in 
underestimation of total IDeg plasma concentration.22
Plasma serum concentrations of Gla-300 and its metabolites 
were quantified using a radio-immunosorbent assay10–12 and 
liquid chromatography coupled to tandem mass 
spectrometry.5,10,11 Both methods had a lower limit of quantitation 
of 30  pmol/l10–12 or less.5 As Gla-300 is not known to be highly 
protein bound, quantitation using immunoassays is expected to 
accurately reflect the total plasma concentration.22
During a glucose clamp study with IDeg at 0.4  IU/kg under 
steady-state conditions a Cmax of approximately 833.3 μU/ml was 
reported.9 Where Gla-300 was used at 0.4  IU/kg under steady-
state conditions, Cmax of approximately 15 μU/ml was reported.
10,12
This distinct difference between the maximum plasma 
concentrations of IDeg and Gla-300 can be attributed to the plasma 
protein bound nature of IDeg if the levels reflect total plasma insulin 
concentration. Fasting plasma concentration of endogenous insulin 
has been reported as 23–36 μU/ml.23 An approximate increase of 
30-fold in plasma insulin concentration is thus observed after 
administration of IDeg in comparison with endogenous insulin.
The results from glucose clamp studies of IDeg and Gla-300 are 
summarised in Table 1.
From the data obtained from glucose clamp studies for the two 
longer-acting analogue insulins, insulin degludec and insulin 
glargine U300, it is clear that there are distinct differences between 
the insulins. Insulin degludec, due to the acetylation of the beta-
chain, is highly plasma protein bound and therefore has an 
extended duration of action of up to 42 h.9 This also results in high 
plasma levels of IDeg determined during glucose clamp studies. 
Gla-300 is similar in structure to insulin glargine U100, but has a 
distinct PK/PD profile with duration of action of up to 36 h.10
Both of these analogue insulins provide flat PD profiles, more 
predictable responses and basal insulin coverage longer than 
24 h, which has not been possible with current insulin treatments. 
These characteristics have been associated with lower incidence 
observed for IDeg between 6 a and 12 h and for Gla-300 between 
0 h and 6  h. It must be considered, however, that the insulins 
used to establish the glucose clamp may still be affecting the GIR 
during the first hours of the glucose clamp therefore potentially 
confounding the observed GIR in the interval following the 
administration of short-acting insulin. Therefore, the use of 
insulin glulisine in establishing clamp target may contribute to 
the slight fluctuation observed in the GIR of Gla-300 in the first 
six-hourly interval. For clamp studies with IDeg the effect of 
human regular insulin used to establish the clamp target may 
affect GIR for the first seven hours of the clamp study.
Recently the results of a euglycemic glucose clamp study 
comparing Gla-300 and IDeg were presented at the Diabetes 
Technology Society conference. The study was performed in a 
population of patients diagnosed with Type 1 DM, under steady-
state conditions of Gla-300 or IDeg at 0.4 IU/kg. Results indicated 
that Gla-300 resulted in less within-day variability in 
glucodynamics than IDeg.19 Complete results of the study have 
not yet been published.
Plasma insulin concentration
In order to determine the pharmacokinetic profile of longer-
acting basal analogue insulins, the plasma insulin concentration 
Figure 1: Diurnal fluctuations in the glucodynamics of IDeg9 and  
Gla-300.12
Notes: The glucose clamp studies were performed at a steady-state of IDeg and 
Gla-300. A dose of 0.4 IU/kg was used for both longer-acting basal analogue 
insulins.
Table 1: Comparison of published glucose clamp results of insulin 
degludec (IDeg) and insulin glargine U300 (Gla-300)
Factor Insulin degludec Insulin glargine 300
Clamp methodology Biostator7,8 Biostator12 
Duration of clamp study 24 h8 24 h12 
26 h7 36 h5,10,11 
42 h9 
Study population Type 1 DM8,9 Type 1 DM5,10–12
Type 2 DM7 
Dose of study insulin 0.4, 0.6, 0.8 IU/kg7–9 0.4, 0.6, 0.9 IU/kg/
day5,10–12 
Steady state Yes7–9 Yes5,10,12 
No11
Maximum plasma insulin 
concentration (study 
insulin at 0.4 IU/kg)
Approx. 833.3 μU/ml9 15 μU/ml10,12
10.9 and 8.9 μU/ml11
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units.mL−1. Diabetes Care. 2014;1–7.
11.  Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml 
provides prolonged, stable glycaemic control in Japanese and European 
people with type 1 diabetes. Diabetes Obes Metab. 2015;17: 254–60. 
https://doi.org/10.1111/dom.2015.17.issue-3
12.  Becker RHA, Nowotny I, Teichert L, et al. Low within- and between-
day variability in exposure to new insulin glargine 300 U/ml. Diabetes 
Obes Metab. 2015;17: 261–7. https://doi.org/10.1111/dom.2015.17.
issue-3
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org/10.1007/s00125-008-1098-5
14.  Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and 
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continuous subcutaneous infusion of insulin lispro. Diabetes. 2000; 49:2142 
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https://doi.org/10.2337/diacare.28.5.1077
19.  Bailey T, Dahmen, R, Petthus J, et al. Insulin glargine 300 U/ml (Gla-
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Diabetes Techology Society; 2016 10–12 November 2016, Bethesda, 
MD, USA.
20.  Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding of 
insulins acylated with fatty acids: characterization of the ligand-
protein interaction and correlation between binding affinity and 
timing of the insulin effect in vivo. Biochem. J. 1995;312(3): 725–31. 
https://doi.org/10.1042/bj3120725
21.  Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the 
novel protraction mechanism of insulin degludec, an ultra-
long-acting basal insulin. Pharm Res. 2012;29: 2104–24. 
https://doi.org/10.1007/s11095-012-0739-z
22.  Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal 
insulins. Ther Clin Risk Manag. 2016;12: 389–400.
23.  Weyer C, Hanson RL, Tataranni PA., et al. A high fasting plasma 
insulin concentration predicts type 2 diabetes independent 
of insulin resistance: evidence for a pathogenic role of 
relative hyperinsulinemia. Diabetes. 2000;49: 2094–2101. 
https://doi.org/10.2337/diabetes.49.12.2094
24.  Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-long 
acting basal insulin, versus insulin glargine in basal-bolus 
treatment with mealtime insulin aspart in type 1 diabetes 
(BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, 
treat-to-target non-inferiority trial. Lancet. 2012;379: 1489–97. 
https://doi.org/10.1016/S0140-6736(12)60204-9
25.  Garber AJ, King AB, Prato S, et al. Insulin degludec, an ultra-
long acting basal insulin versus insulin glargine in basal-bolus 
treatment with mealtime insulin aspart in type 2 diabetes (BEGIN 
Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-
to-target non-inferiority trial. Lancet. 2012;379: 1498–1507. 
https://doi.org/10.1016/S0140-6736(12)60205-0
26.  Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec 
versus insulin glargine in insulin-naïve patients with 
type 2 diabetes: a 1-year randomised, treat-to-target trial 
(BEGIN Once Long). Diabetes Care. 2012;35(12): 2464–71. 
https://doi.org/10.2337/dc12-1205
of hypoglycaemia.16 However, effects on hypoglycaemia, 
difference in dosing frequency and intervals of these insulins can 
only be demonstrated conclusively through rigorous large 
clinical studies.
The efficacy and safety of IDeg and Gla-300 have been 
investigated in randomised, controlled phase 3 studies and 
confirm the clinical benefits of the longer-acting insulins in 
comparison to insulin glargine U100. The BEGIN trial programme 
demonstrated that IDeg, when compared with insulin glargine 
U100, is non-inferior with regard to glycaemic control as 
measured by HbA1c and a reduction in the rate of nocturnal, 
confirmed hypoglycaemia was also observed in heterogeneous 
populations of patients diagnosed with diabetes.24–26 When Gla-
300 was compared with insulin glargine U100 in the EDITION 
trial programme, non-inferiority with regard to glycaemic control 
as measured by HbA1c and a reduction in the rate of nocturnal, 
confirmed hypoglycaemia was demonstrated in heterogeneous 
populations of patients diagnosed with diabetes.27–29
Conclusion
The longer-acting basal analogues insulins, IDeg and Gla-300, 
offer the prescriber a wider armamentarium of treatment for 
uncontrolled hyperglycaemia with PD profiles with smaller 
gradients than current basal insulins. However, the effect of the 
more evenly distributed insulin release on the incidence of 
hypoglycaemia of these insulins cannot be concluded from the 
glucose clamp studies at hand: pivotal clinical trial evidence 
remains the gold standard. Armed with a scientifically sound 
understanding of the pharmacokinetic and pharmacodynamic 
properties of new longer-acting basal analogue insulins, the 
treating doctor can utilise these properties to the advantage of 
the patient diagnosed with diabetes.
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more evenly distributed insulin release on the incidence of 
hypoglycaemia of these insulins cannot be concluded from the 
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